Thalidomide treatment in myelofibrosis with myeloid metaplasia.

Elliott MA, Mesa RA, Li CY, Hook CC, Ansell SM, Levitt RM, Geyer SM, Tefferi A

Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study.

Steensma DP, Mesa RA, Li CY, Gray L, Tefferi A

Adverse events after imatinib mesylate therapy.

Elliott MA, Mesa RA, Tefferi A

A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies.

Rajkumar SV, Mesa RA, Tefferi A

Palliative splenectomy in myelofibrosis with myeloid metaplasia.

Mesa RA, Tefferi A

A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia.

Mesa RA, Tefferi A, Elliott MA, Hoagland HC, Call TG, Schroeder GS, Yoon SY, Li CY, Gray LA, Margolin S, Hook CC

Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia.

Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW

Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia.

Mesa RA, Li CY, Schroeder G, Tefferi A

Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia.

Tefferi A, Elliot MA, Yoon SY, Li CY, Mesa RA, Call TG, Dispenzieri A

Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia.

Tefferi A, Jiménez T, Gray LA, Mesa RA, Chen MG